Evaluating XXXX treatment in @entity1 with low-risk postmolar @entity1469 .

@entity1 @entity1469 @entity1500 @entity3 @entity1499
OBJECTIVE: To identify clinical factors associated with requiring more than a single course of @entity1499 ( @entity1500 ) to achieve remission among @entity1 with low-risk postmolar @entity1469 ( @entity1469 ). METHODS: We studied 150 @entity1 with persistent @entity1469 after diagnosis of complete (n=110) or partial mole (n=40) to identify possible predictors of requiring additional treatment after a single treatment of @entity1499 ( @entity1500 ). All @entity1 had low-risk disease using FIGO and WHO scoring systems. RESULTS: Seventy @entity1 (47%) required additional courses of chemotherapy, of whom 45 (64%) received chemotherapy other than @entity1500 . Multivariate analysis revealed that complete mole histology, presence of @entity3 , single day @entity1500 infusion and any increase in serum beta @entity1 chorionic gonadotropin (beta-hCG) level 1 week after @entity1500 therapy were independent predictors of requiring additional @entity1500 or alternative chemotherapy. Dilatation and curettage (D+C) within 1 week after the diagnosis of persistence did not affect future chemotherapy requirements (p>0.64). Following complete mole, beta-hCG levels >2000 mIU/mL at 1 week post @entity1500 were associated with a 89% risk of additional cycles chemotherapy including @entity1500 and a 65% risk of alternative chemotherapy. CONCLUSIONS: @entity3 , @entity1500 infusion protocol and complete mole histology were independently associated with the need for additional chemotherapy after an initial course of @entity1500 for @entity1 with low risk @entity1469 . D+C at persistence did not alter the chemotherapy requirement. Elevated beta-hCG level at 1 week after the initial course of @entity1500 was also an independent factor predicting the need for additional courses of @entity1500 or alternative chemotherapy.
